본문으로 건너뛰기
cccskills
무료GitHub에 공개

jes-pa-mra-selection

Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

설치 방법 보기

포함된 파일(1)

  • SKILL.md2.9 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

Select appropriate mineralocorticoid receptor antagonist for PA treatment

STEP 1 — Gather Information

Collect gender, pregnancy status, need for potassium supplementation, history of gynecomastia, renal/hepatic function, cost/insurance coverage, and patient preference.
→ Proceed to assess potassium supplementation need.

STEP 2 — Rule In / Rule Out

If the patient requires potassium supplementation → select spironolactone (can be combined with K+ prep) and arrange K+ and creatinine monitoring; else → proceed to evaluate gynecomastia risk.
→ Proceed to assess gynecomastia concern.

STEP 3 — Classify or Stratify

If the patient is male with concern for gynecomastia → exclude spironolactone and consider eplerenone or esaxerenone; else → consider all three MRAs.
→ Proceed to final selection based on cost, adverse effect profile, and tolerability.

STEP 4 — Decide

Choose the MRA that best balances cost, adverse effect profile (e.g., esaxerenone lower gynecomastia risk but limited long-term data), and patient preferences; prescribe at starting dose (spironolactone 25 mg daily, eplerenone 2.5 mg daily, esaxerenone 1.25 mg daily) with potassium and renal monitoring.
→ Initiate selected MRA and schedule follow‑up in 1–2 weeks.

Clinical Guardrails / Mimics / Pitfalls

  • Avoid eplerenone or esaxerenone with potassium supplements due to heightened hyperkalemia risk.
  • Avoid spironolactone in pregnancy (anti‑androgen effects); consider eplerenone or esaxerenone if pregnancy is planned.
  • Monitor serum potassium and creatinine within 1–2 weeks of initiation and periodically thereafter.
  • Watch for spironolactone‑induced gynecomastia in males and menstrual irregularities in females.
  • Consider cost and insurance coverage; esaxerenone may have less long‑term outcome data than spironolactone or eplerenone.
  • In severe renal impairment, all MRAs require caution; follow dosing restrictions per label.

Concrete Clinical Example

A 62‑year‑old male with bilateral PA presents with persistent hypokalemia requiring oral potassium chloride. He has no gynecomastia concern. Because he needs potassium supplementation, spironolactone is selected (can be combined with K+ prep). Start spironolactone 25 mg daily; check potassium and creatinine in 1 week.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021, DOI: 10.1007/s00223-022-00903-5

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

dromlakhani의 스킬 모두 보기

이 스킬의 문제 신고